Skip to main content
  • Login
  • Contact
  • Subscriptions

Search form

Home

Deer Park Tribune

Deer Park weather

  • Home
  • News
  • Sports
  • Obituaries
  • Entertainment
    • Special Sections
    • Talking About...
  • Photos
  • Videos
  • Classifieds
    • Classified Display Ads
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
Gold
Crude Oil
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Mirati Therapeutics (NQ: MRTX )

158.19 USD -5.86 (-3.57%)
Official Closing Price Updated: 5:07 PM EDT, Apr 16, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 559,300
Open 164.76
Bid (Size) 158.19 (8)
Ask (Size) 158.31 (7)
Prev. Close 164.05
Today's Range 154.93 - 164.76
52wk Range 80.36 - 249.42
Shares Outstanding 50,633,981
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Mirati Therapeutics Presents Preclinical Data on Novel Approach to PRMT5 Inhibition that Selectively Targets the PRMT5/MTA Complex in MTAP-Deleted Cancer Models
April 10, 2021
Internally discovered PRMT5 program represents a potential first-in-class approach to specifically target MTAP-deleted tumors 
From PR Newswire
Mirati Therapeutics Board Elects Shalini Sharp as New Independent Director
March 31, 2021
Mirati Therapeutics, Inc. (NASDAQ: MRTX), a late-stage targeted oncology company, today announced its Board of Directors has elected a new independent director, Ms. Shalini Sharp. 
From PR Newswire

Performance

YTD
-28.62%
-28.62%
1 Month
-11.03%
-11.03%
3 Month
-26.87%
-26.87%
6 Month
-18.83%
-18.83%
1 Year
+74.41%
+74.41%

More News

Read More
Mirati Therapeutics to Present Late-Breaking Data That Advance the Understanding of Synthetic Lethal PRMT5 Inhibitors in MTAP-Deleted Cancers at AACR 2021
March 10, 2021
From PR Newswire
Mirati Therapeutics Reports Fourth Quarter And Full-Year 2020 Financial Results And Recent Corporate Updates
February 25, 2021
From PR Newswire
Mirati Therapeutics To Present At Upcoming Healthcare Conferences
February 18, 2021
From PR Newswire
MD Anderson And Mirati Therapeutics Announce KRAS Strategic Research And Development Collaboration In Solid Tumors
February 10, 2021
From PR Newswire
Mirati Therapeutics To Present At Guggenheim Healthcare Talks 2021 Oncology Days
February 04, 2021
From PR Newswire
Analysts Anticipate ANEW To Hit $48
March 17, 2021
Tags ETFs
From ETF Channel
7 Biotech Stocks With Catalysts That Go Far Beyond Covid-19 Vaccines
March 12, 2021
Tags ZLAB FATE DNLI
From InvestorPlace
7 Pharmaceutical Stocks Working on Their Next Blockbuster
March 12, 2021
Tags ARGX NVO BMRN
From InvestorPlace
This 2020 Biotech IPO Is Poised to Break Out in 2021
April 02, 2021
Tags MRK SNY RVMD
From Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Copyright © 2020 The Deer Park Tribune | 104 N. Main Street | Deer Park, WA 99006 | (509) 276-5043
All property rights for the entire contents of this publication shall be the property of The Deer Park Tribune.
No part hereof may be reproduced without prior written consent.
Privacy and Terms of Use


Site Design, Programming & Development by Surf New Media